Departing from Tucson headquarters to New Orleans, our team plans extensive in-person communication with global cell and gene therapy, cancer immunotherapy industry peers. We aim to reconnect with long-term cooperative partners and explore new potential collaborators at the conference, discussing cutting-edge progress across CAR-T detection, anti-idiotype antibody development and in vivo CAR-T preclinical research.
All attendees who will join ASGCT 2025 are welcome to get in touch in advance to schedule face-to-face technical discussion at the venue.